← The Wire
URGNNasdaq
UroGen Pharma Ltd.
Pharmaceutical Preparations · L3 · CIK 1668243
UroGen Pharma develops and commercializes innovative solutions for urothelial and specialty cancers using its RTGel technology
red 8-K · 90d
$1.45B
Market cap
$36.07
Last close
+4.4%
1D
+3.1%
5D
600K
Volume
Price · last 39 sessions+54.9%
May 4L $23.29 · H $36.07Jun 29
189
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Security-Holder RightsJun 23, 20268-KCompany UpdateJun 2, 202610-QFORM 10-QMay 6, 20268-KResults of OperationsMay 6, 2026DEF 14AFORM DEF 14AApr 30, 202610-KFORM 10-KMar 2, 20268-KResults of OperationsMar 2, 20268-KMaterial Agreement · New Debt / ObligationMar 2, 202610-QFORM 10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KExecutive Change · Shareholder VoteAug 27, 202510-QFORM 10-QAug 7, 20258-KResults of OperationsAug 7, 2025DEF 14AFORM DEF 14AJul 15, 20258-KExecutive ChangeJul 3, 20258-KCompany UpdateJun 13, 202510-QFORM 10-QMay 12, 20258-KResults of OperationsMay 12, 202510-K/AFORM 10-K/AApr 30, 202510-KFORM 10-KMar 10, 20258-KResults of OperationsMar 10, 20258-KMaterial Agreement · Equity IssuanceFeb 20, 20258-KReg FD DisclosureJan 14, 2025SC 13GUROGEN PHARMA LTD.Nov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GMS INITIALNov 6, 202410-QFORM 10-QNov 6, 20248-KResults of OperationsNov 6, 2024SC 13GSC 13GOct 24, 20248-KExecutive ChangeOct 9, 20248-KNew Debt / ObligationSep 24, 20248-KExecutive ChangeSep 13, 20248-KCompany UpdateAug 15, 202410-QFORM 10-QAug 13, 20248-KResults of OperationsAug 13, 20248-KExecutive Change · Shareholder VoteAug 8, 2024DEFA14AFORM DEFA14AJul 1, 2024DEF 14AFORM DEF 14AJul 1, 2024SC 13GCOWEN AND COMPANY, LLCJun 24, 2024SC 13GUROGEN PHARMA LTD.Jun 24, 20248-KMaterial Agreement · Company UpdateJun 18, 2024424B5424B5Jun 18, 2024424B5424B5Jun 17, 20248-KReg FD Disclosure · Company UpdateJun 13, 202410-QFORM 10-QMay 13, 20248-KResults of OperationsMay 13, 202410-K/AFORM 10-K/AApr 29, 202410-KFORM 10-KMar 14, 20248-KResults of OperationsMar 14, 20248-KReg FD DisclosureMar 4, 20248-KReg FD DisclosureMar 1, 2024SC 13GUROGEN PHARMA LTD.Feb 14, 20248-KReg FD DisclosureFeb 7, 2024SC 13GSC 13GFeb 2, 20248-KMaterial Agreement · Company UpdateJan 17, 20248-KMaterial AgreementJan 2, 2024SC 13GSC 13GDec 29, 202310-QFORM 10-QNov 14, 20238-KResults of OperationsNov 14, 2023SC 13GSC 13GSep 15, 20238-KExecutive Change · Shareholder VoteSep 11, 202310-QFORM 10-QAug 10, 20238-KResults of OperationsAug 10, 2023SC 13DSC 13DAug 4, 2023DEFA14AFORM DEFA14AAug 1, 2023DEF 14AFORM DEF 14AAug 1, 20238-KMaterial Agreement · Equity IssuanceJul 27, 20238-KExecutive ChangeJul 25, 20238-KResults of OperationsMay 11, 202310-QFORM 10-QMay 11, 202310-K/A10-K/AMay 1, 202310-KFORM 10-KMar 24, 20238-KResults of OperationsMar 22, 2023SC 13GSC 13GDec 1, 2022424B5424B5Dec 1, 20228-KResults of OperationsNov 10, 202210-QFORM 10-QNov 10, 20228-KExecutive ChangeNov 9, 20228-KNew Debt / ObligationOct 21, 20228-KExecutive ChangeSep 12, 2022
Insider Activity
In the 90 days to Feb 3, 2026: 2 sold $542K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 3,686 | $19.69 | $73K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 3,217 | $19.69 | $63K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 2,654 | $19.69 | $52K |
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 1,844 | $19.69 | $36K |
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 1,843 | $19.69 | $36K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 1,608 | $19.69 | $32K |
| Nov 19, 2025 | Schoenberg MarkChief Medical Officer | Sell | 10,000 | $25.00 | $250K |
| Oct 8, 2025 | Degnan ChrisChief Financial Officer | Sell | 2,203 | $16.85 | $37K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance